A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months

A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months

This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16–24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-...

Full description

Bibliographic Details
Main Authors: Hitt Sharma, Sanjay Lalwani, Sameer Parekh, Pramod Pujari, Sunil Shewale, Sonali Palkar, Neeta Hanumante, Shilpa Gokhale, Jaganathan Ks, Rakesh Kumar, Inderjit Sharma, Sunil Gairola
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hexavalent
toddler
phase i
vaccine
safety
Online Access:http://dx.doi.org/10.1080/21645515.2022.2146435

Similar Items

Similar Items